Jazz Pharmaceuticals (JAZZ) Guidance Looks Conservative After Printing a 43% Conversion Rate - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $174.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) after revenues ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
